|

UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy

RECRUITINGPhase 2Sponsored by University of Alabama at Birmingham
Actively Recruiting
PhasePhase 2
SponsorUniversity of Alabama at Birmingham
Started2018-04-20
Est. completion2028-10
Eligibility
Age50 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT03503331

Summary

The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer \[C-11\]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with \[C-11\]PiB-PET, and cognitive status will be the primary outcome of this imaging study.

Eligibility

Age: 50 Years+Healthy volunteers accepted
Inclusion Criteria:

\- 1. Enrollment in the UAB-ADC study under a separate IRB-approved research protocol (IRB-300000169).

2\. Negative urine or serum B-hCG test within 2 days of \[C-11\]PiB administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.

Exclusion Criteria:

1. Meets any exclusion criteria for the UAB-ADC study (IRB-300000169).
2. Inability or contraindication for undergoing MRI and/or PET imaging
3. Inability to participate in the imaging studies due to severity of dementia

Conditions2

Alzheimer DiseaseAlzheimer's Disease

Locations1 site

University of Alabama at Birmingham Medical Center
Birmingham, Alabama, 35294
Jonathan McConathy, MD205-996-7115jmcconathy@uabmc.edu

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.